Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV000994218 | SCV001147582 | likely pathogenic | not provided | 2018-12-01 | criteria provided, single submitter | clinical testing | |
Molecular Genetics Laboratory, |
RCV001199673 | SCV001162487 | pathogenic | Retinitis pigmentosa | 2020-01-09 | criteria provided, single submitter | research | |
Genome- |
RCV003455016 | SCV004180068 | likely pathogenic | Retinitis pigmentosa 12 | 2023-04-11 | criteria provided, single submitter | clinical testing | |
Invitae | RCV003769329 | SCV004593139 | likely pathogenic | Retinitis pigmentosa 12; Leber congenital amaurosis 8 | 2022-12-14 | criteria provided, single submitter | clinical testing | In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. This variant disrupts the p.Cys896 amino acid residue in CRB1. Other variant(s) that disrupt this residue have been observed in individuals with CRB1-related conditions (PMID: 27353947, 33090715, 33579689), which suggests that this may be a clinically significant amino acid residue. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt CRB1 protein function. ClinVar contains an entry for this variant (Variation ID: 806308). This missense change has been observed in individual(s) with retinitis pigmentosa (PMID: 32531858). This variant is not present in population databases (gnomAD no frequency). This sequence change replaces cysteine, which is neutral and slightly polar, with tyrosine, which is neutral and polar, at codon 896 of the CRB1 protein (p.Cys896Tyr). |